DelveInsight’s “Dementia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dementia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Dementia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dementia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Dementia: An Overview
Dementia describes an overall decline in memory and other thinking skills severe enough to reduce a person’s ability to perform everyday activities. It is characterized by the progressive and persistent deterioration of cognitive function. Patients with dementia have problems with cognition, behavior, and functional activities of everyday life. In addition, affected patients have memory loss and a lack of insight into their problems.
FDA-approved medications to improve cognitive functions include cholinesterase inhibitors and memantine. Cholinesterase inhibitors are donepezil, galantamine, and rivastigmine. Cholinesterase inhibitors prevent the breakdown of acetylcholine and can slow or delay the worsening of symptoms. Memantine is an NMDA antagonist and decreases the activity of glutamine. Donepezil is approved for all stages of Alzheimer’s disease, galantamine, and rivastigmine for the mild to moderate stage, and memantine for the moderate to severe stage.
On April 3, 2023, Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”) announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for a phase I/IIA clinical trial under its Investigational New Drug (“IND”) application for immunotherapy (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dementia pipeline therapies. It also thoroughly assesses the Dementia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Dementia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Dementia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Dementia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Dementia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
Dementia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Dementia market or expected to be launched during the study period. The analysis covers the Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Dementia drugs based on their sale and market share.
The report also covers the Dementia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Dementia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Dementia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/dementia-market
Dementia Companies Actively Working in the Therapeutics Market Include
-
Applied Genetic Technologies Corporation
-
Neurimmune
-
Passage Bio, Inc.
-
Denali Therapeutics
-
Alector Inc.
-
AriBio
-
Aphios Corporation
-
Asceneuron
-
CuraSen Therapeutics
-
Cognition Therapeutics
And Many Others
Emerging and Marketed Dementia Therapies Covered in the Report Include:
-
AGTC-601
-
NI308
-
PBFT02
-
DNL593
-
AL001
-
AR1001
-
APH-1104
-
ASN51
-
CST-103
-
CT1812
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/dementia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Dementia Competitive Intelligence Analysis
4. Dementia Market Overview at a Glance
5. Dementia Disease Background and Overview
6. Dementia Patient Journey
7. Dementia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Dementia Treatment Algorithm, Current Treatment, and Medical Practices
9. Dementia Unmet Needs
10. Key Endpoints of Dementia Treatment
11. Dementia Marketed Therapies
12. Dementia Emerging Drugs and Latest Therapeutic Advances
13. Dementia Seven Major Market Analysis
14. Attribute Analysis
15. Dementia Market Outlook (In US, EU5, and Japan)
16. Dementia Companies Active in the Market
17. Dementia Access and Reimbursement Overview
18. KOL Views on the Dementia Market
19. Dementia Market Drivers
20. Dementia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/dementia-market
About DelveInsight
DelveInsight is a leading business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Dupuytren’s Disease Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Dupuytren’s Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Dupuytren’s Disease market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices